Dr. Mannick is a leading expert in the mTOR and geroscience fields and has over 15 years of drug development expertise. She has led mTOR inhibitor clinical development programs both as the Co-Founder and Chief Medical Officer of resTORbio, now Adicet Bio, and as an Executive Director of the New Indications Discovery Unit at the Novartis Institutes of Biomedical Research. She previously served as Head of Research and Development at Life Biosciences and was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme she served as a faculty member at Harvard Medical School and University of Massachusetts Medical School. She received an A.B. from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women's Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program.

Vrej Jubian is a Director, API Manufacturing and Drug Product, CMC. With over 25 years experience in pharmaceutical, biotech and chemical industries, he brings expertise in chemical development of small organic molecules from the discovery stage to the clinic.  Prior to joining Cambrian, He served in the Business Management group at Thermo Fisher’s API drug substance division providing technical assessments and solutions for clients looking to develop their clinical candidates.  Before Thermo Fisher, he worked as the CMC Manager for Synaptic Pharmaceuticals and subsequently as a Principal Scientist for Lundbeck.  He managed outsourcing activities for development programs and internal medchem projects. He also headed a scale-up lab and provided leadership in drug discovery projects where his group identified several drug development candidates targeting novel GPCRs for CNS therapeutics.  Vrej received his PhD in organic chemistry from McGill University (Montreal, Canada) and completed his postdoctoral training at University of Pittsburgh.

Wenjie Luo serves as Business Operations Manager at Cambrian Bio. Prior to joining Cambrian, she was the Senior Business Development Associate at Cresilon, a biotechnology startup, where she led numerous initiatives to better the company's business development and operations, including securing a $3M non-dilutive capital grant to expand the company's regional footprint. She has also served as a researcher at academic laboratories at Columbia and Cornell Universities. Luo earned her Master of Science in Biomedical Engineering from Columbia University and Bachelor of Science in Biological Engineering from Cornell University.